|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/09/16 Unitedhealth Group Inc 10-K 12/31/15 113:19M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.47M
2: EX-10.24 Material Contract HTML 40K
3: EX-10.40 Material Contract HTML 76K
5: EX-21.1 Subsidiaries List HTML 149K
6: EX-23.1 Consent of Experts or Counsel HTML 33K
7: EX-24.1 Power of Attorney HTML 40K
4: EX-12.1 Statement re: Computation of Ratios HTML 45K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 48K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 36K
16: R1 Document and Entity Information Document HTML 62K
17: R2 Consolidated Balance Sheets HTML 129K
18: R3 Consolidated Balance Sheet (Parenthetical) HTML 60K
19: R4 Consolidated Statements of Operations HTML 102K
20: R5 Consolidated Statements of Comprehensive Income HTML 70K
21: R6 Consolidated Statements of Changes in Equity HTML 102K
22: R7 Consolidated Statements of Cash Flows HTML 131K
23: R8 Description of Business (Notes) HTML 34K
24: R9 Basis of Presentation, Uses of Estimates and HTML 135K
Significant Accounting Policies (Notes)
25: R10 Business Combination (Notes) HTML 59K
26: R11 Investments (Notes) HTML 260K
27: R12 Fair Value (Notes) HTML 331K
28: R13 Property, Plant, and Capitalized Software (Notes) HTML 56K
29: R14 Goodwill and Intangible Assets (Notes) HTML 120K
30: R15 Medical Costs Payable (Notes) HTML 59K
31: R16 Commercial Paper and Long-Term Debt (Notes) HTML 249K
32: R17 Income Taxes (Notes) HTML 156K
33: R18 Stockholders' Equity (Notes) HTML 56K
34: R19 Share-Based Compensation (Notes) HTML 115K
35: R20 Commitments and Contingencies (Notes) HTML 57K
36: R21 Segment Financial Information (Notes) HTML 313K
37: R22 Quarterly Financial Data (Unaudited) (Notes) HTML 85K
38: R23 Schedule I (Notes) HTML 190K
39: R24 Basis of Presentation, Uses of Estimates and HTML 202K
Significant Accounting Policies (Policies)
40: R25 Fair Value Fair Value (Policies) HTML 48K
41: R26 Basis of Presentation, Uses of Estimates and HTML 100K
Significant Accounting Policies (Tables)
42: R27 Business Combination (Tables) HTML 69K
43: R28 Investments (Tables) HTML 258K
44: R29 Fair Value (Tables) HTML 323K
45: R30 Property, Plant, and Capitalized Software (Tables) HTML 54K
46: R31 Goodwill and Intangible Assets (Tables) HTML 123K
47: R32 Medical Costs Payable (Tables) HTML 60K
48: R33 Commercial Paper and Long-Term Debt (Tables) HTML 252K
49: R34 Income Taxes (Tables) HTML 157K
50: R35 Stockholders' Equity (Tables) HTML 41K
51: R36 Share-Based Compensation (Tables) HTML 114K
52: R37 Commitments and Contingencies (Tables) HTML 43K
53: R38 Segment Financial Information (Tables) HTML 300K
54: R39 Quarterly Financial Data (Unaudited) (Tables) HTML 84K
55: R40 Schedule I (Tables) HTML 196K
56: R41 Basis of Presentation, Uses of Estimates and HTML 85K
Significant Accounting Policies (Details)
57: R42 Basis of Presentation, Uses of Estimates and HTML 41K
Significant Accounting Policies Medicare Part D
(Details)
58: R43 Basis of Presentation, Uses of Estimates and HTML 44K
Significant Accounting Policies Useful lives for
property, equipment and capitalized software
(Details)
59: R44 Basis of Presentation, Uses of Estimates and HTML 56K
Significant Accounting Policies Redeemable
Noncontrolling Interests (Details)
60: R45 Basis of Presentation, Uses of Estimates and HTML 45K
Significant Accounting Policies Future Policy
Benefits and Reinsurance Receivables (Details)
61: R46 Business Combination (Details) HTML 66K
62: R47 Business Combination Acquired Assets and HTML 51K
Liabilities (Details)
63: R48 Business Combination Acquired finite-lived HTML 49K
intangible assets (Details)
64: R49 Investments (Narrative) (Details) HTML 36K
65: R50 Investments (Short-Term and Long-Term Investments) HTML 98K
(Details)
66: R51 Investments (Amortized Cost and Fair Value of HTML 108K
Available-for-Sale Debt Securities by Contractual
Maturity) (Details)
67: R52 Investments (Fair Value of Available-For-Sale HTML 76K
Investments with Gross Unrealized Losses by
Investment Type and Length of Time That Individual
Securities Have Been in a Continuous Unrealized
Loss Position) (Details)
68: R53 Investments (Net Realized Gains) (Details) HTML 57K
69: R54 Fair Value (Narrative) (Details) HTML 57K
70: R55 Fair Value (Financial Assets and Liabilities, HTML 100K
Excluding AARP, Measured at Fair Value on a
Recurring Basis) (Details)
71: R56 Fair Value (Financial Assets and Liabilities, HTML 93K
Excluding AARP, Not Measured at Fair Value on a
Recurring Basis) (Details)
72: R57 Fair Value (Reconciliation of Assets Measured at HTML 56K
Fair Value on a Recurring Basis Using Level 3
Inputs) (Details)
73: R58 Fair Value Fair Value Inputs Assets Quantitative HTML 52K
Information (Details)
74: R59 Fair Value (Assets and Liabilities measured at HTML 115K
fair value on a recurring basis) (Details)
75: R60 Property, Plant, and Capitalized Software HTML 37K
(Details)
76: R61 Property, Plant, and Capitalized Software Property HTML 57K
Plant and Equipment Table (Details)
77: R62 Goodwill and Intangible Assets (Details) HTML 35K
78: R63 Goodwill and Intangible Assets Changes in the HTML 52K
Carrying Amount of Goodwill by Reporting Segment
(Details)
79: R64 Goodwill and Intangible Assets Gross carrying HTML 51K
value, accumulated amortization and net carrying
value of intangible assets (Details)
80: R65 Goodwill and Intangible Assets Weighted-average HTML 45K
useful lives assigned to finite-lived intangible
assets acquired in business combinations (Details)
81: R66 Goodwill and Intangible Assets Amortization HTML 44K
Expense relating to Intangible Assets (Details)
82: R67 Medical Costs Payable Rollforward (Details) HTML 52K
83: R68 Commercial Paper and Long-Term Debt (Narrative) HTML 82K
(Details)
84: R69 Commercial Paper and Long-Term Debt (Details) HTML 187K
85: R70 Commercial Paper and Long-Term Debt Maturities of HTML 49K
commercial paper and long-term debt (Details)
86: R71 Commercial Paper and Long-Term Debt Fair Value HTML 46K
Hedges Statement of Financial Position Location
(Details)
87: R72 Commercial Paper and Long-Term Debt Fair Value HTML 46K
Hedges Effect of Changes in Fair Value Hedges on
Income (Details)
88: R73 Income Taxes (Details) HTML 60K
89: R74 Income Taxes Reconciliation of Provision for HTML 49K
Income Taxes (Details)
90: R75 Income Tax Reconciliation of the tax provision at HTML 72K
the U.S. Federal Statutory Rate (Details)
91: R76 Income Taxes Components of Deferred Tax Assets and HTML 89K
Liabilities (Details)
92: R77 Income Taxes Reconciliation of the beginning and HTML 49K
ending amount of unrecognized tax benefits
(Details)
93: R78 Stockholders' Equity (Details) HTML 65K
94: R79 Stockholders' Equity Dividends Paid (Details) HTML 37K
95: R80 Share-Based Compensation Narrative (Details) HTML 42K
96: R81 Share-Based Compensation (Stock Option and SAR HTML 78K
Activity) (Details)
97: R82 Share-Based Compensation (Restricted Share HTML 50K
Activity) (Details)
98: R83 Share-Based Compensation Other Share-Based HTML 64K
Compensation Data (Details)
99: R84 Share-Based Compensation (Share-Based Compensation HTML 51K
Principal Fair Value Assumptions) (Details)
100: R85 Commitments and Contingencies (Details) HTML 55K
101: R86 Commitments and Contingencies Future Lease HTML 48K
Payments (Details)
102: R87 Segment Financial Information (Narrative) HTML 47K
(Details)
103: R88 Segment Financial Information (Details) HTML 124K
104: R89 Quarterly Financial Data (Unaudited) (Details) HTML 65K
105: R90 Schedule I (Details) HTML 56K
106: R91 Schedule I Condensed Balance Sheets (Details) HTML 110K
107: R92 Schedule I Balance Sheet Document (Details) HTML 54K
108: R93 Schedule I Condensed Statement of Comprehensive HTML 71K
Income (Details)
109: R94 Schedule I Statement of Cash Flows (Details) HTML 96K
110: R95 Schedule I Maturities of Commercial Paper and HTML 52K
Long-Term Debt (Details)
112: XML IDEA XML File -- Filing Summary XML 210K
111: EXCEL IDEA Workbook of Financial Reports XLSX 149K
10: EX-101.INS XBRL Instance -- unh-20151231 XML 6.80M
12: EX-101.CAL XBRL Calculations -- unh-20151231_cal XML 321K
13: EX-101.DEF XBRL Definitions -- unh-20151231_def XML 1.62M
14: EX-101.LAB XBRL Labels -- unh-20151231_lab XML 2.71M
15: EX-101.PRE XBRL Presentations -- unh-20151231_pre XML 1.84M
11: EX-101.SCH XBRL Schema -- unh-20151231 XSD 260K
113: ZIP XBRL Zipped Folder -- 0000731766-16-000058-xbrl Zip 470K
| Exhibit |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the
registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
President and Chief Financial Officer | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/9/16 | 4, NO ACT | ||
| For Period end: | 12/31/15 | 11-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/26/16 SEC UPLOAD¶ 10/06/17 1:36K UnitedHealth Group Inc. 3/18/16 SEC UPLOAD¶ 10/06/17 1:158K UnitedHealth Group Inc. |